BMY Q3 2022 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q3 2022 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.2B-3.5% YoY

Gross Profit

$6.4B57.5% margin

Operating Income

$2.2B19.9% margin

Net Income

$1.6B14.3% margin

EPS (Diluted)

$0.75

QoQ Revenue Growth

-5.6%

Cash Flow

Operating Cash Flow

$3.7B

Free Cash Flow

$3.4B

Stock-Based Comp.

$115M

Balance Sheet

Total Assets

$98.2B

Total Liabilities

$65.5B

Stockholders' Equity

$32.7B

Cash & Equivalents

$7.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.2B	$11.6B	-3.5%
Gross Profit	$6.4B	$6.8B	-4.8%
Operating Income	$2.2B	$1.7B	+28.8%
Net Income	$1.6B	$1.5B	+3.9%

Revenue Segments

Eliquis

$2.7B24%

Revlimid

$2.4B22%

Opdivo

$2.0B18%

Pomalyst/Imnovid

$886M8%

Orencia

$883M8%

Sprycel

$560M5%

Yervoy

$523M5%

Mature Products And All Other

$441M4%

Reblozyl

$190M2%

Abraxane

$177M2%

Abecma

$107M1%

Opdualag

$84M1%

Zeposia

$69M1%

Breyanzi

$44M0%

Camzyos

$5M0%

Sotyktu

$1M0%

Geographic Segments

UNITED STATES

$7.9B71%

Rest Of World

$3.1B27%

Other Region

$215M2%